The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05936-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von O Ortmann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93055, Regensburg, Germany. olaf.ortmann@klinik.un…. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Regensburg.
Abstract (Originalsprache)
Purpose
To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions.
Methods
Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers of probably pathogenic and pathogenic variants in BRCA1 or BRCA2 ( BRCA1/2 -pV), in other breast and ovarian cancer genes and the Lynch Syndrome. Cancer risks were compared with data on risks for the general population.
Results
Data on risk modulation of endocrine interventions in women with genetic predisposition is limited. Ovarian hyperstimulation for fertility treatment may be performed. Oral contraceptives should not be used to reduce ovarian cancer risk in BRCA1/2 -pV carriers. Premenopausal BRCA1/2 -pV carriers and carriers of pV in Lynch Syndrome genes should be offered hormone replacement therapy (HRT) after RRSO, to prevent diseases caused by estrogen deficiency.
Conclusion
Effect direction and strength of risk modulation by endocrine interventions is similar to the general population. Participation of individuals at risk in prospective registries is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93055, Regensburg, Germany. olaf.ortmann@klinik.uni-regensburg.de.
- Department of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93055, Regensburg, Germany.
- Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology, Medical Faculty, University Hospital Cologne, Cologne, Germany.
Förderung
- Universitätsklinikum Regensburg
Zitieren
APA
Ortmann, O., Schüler-Toprak, S., Kast, K., & working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC) (2024). The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05936-7
Vancouver
Ortmann O, Schüler-Toprak S, Kast K, working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC). The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05936-7
BibTeX
@article{Ortmann2024,
author = {Ortmann, O and Schüler-Toprak, S and Kast, K and working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC), working group “Hormones”, The German Consortium for Hereditary Breast, Ovarian Cancer (GC-HBOC)},
title = {The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05936-7}
}
EUVIMED